Related Experiment Video
Updated: Jan 11, 2026

Ultrasound Cyclo Plasty in Eyes with Glaucoma
Published on: January 26, 2018
Comparison of Ahmed Glaucoma Valve Implantation Alone Versus Combined with Phacoemulsification in Chinese Primary
Lin Fu1, Xinyi Liu1,2, Yijing Ping1
1National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, People's Republic of China.
Introduction:
To compare the surgical outcomes of Ahmed glaucoma valve (AGV) implantation and combined AGVwith phacoemulsification (Phaco-AGV) in Chinese patients with primary open-angle glaucoma (POAG).
Methods:
A total of 43 eyes followed up for 2 years were enrolled. The primary outcome was the success rate. The success rate was defined as an IOP of 5-21 mmHg (success rate 1) or 5-18 mmHg (success rate 2), and an IOP reduction of more than 20% with (qualified) or without (complete) glaucoma medications. The secondary outcomes included IOP, glaucoma medications, and complications.
Results:
Eighteen eyes underwent AGV and 25 eyes underwent phaco-AGV. There were no differences in the preoperative IOP (25.7 ± 10.7 mmHg vs 26.3 ± 6.2 mmHg, P<0.05) and medications (2.1 ± 1.4 vs 1.6 ± 0.8, P<0.05) between the two groups. The complete success rate 1 in the Phaco-AGV group was higher than that in the AGV group at the 2-year (60.0% vs 22.2%, P<0.05) follow-up. The qualified and complete success rates 2 in the Phaco-AGV group were both higher than those in the AGV group at the 2-year follow-up (all P < 0.05). Patients in the Phaco-AGV group showed significantly lower postoperative IOP at 3 months (P<0.05), used fewer glaucoma medications at month-3, month-6 and year-2 visits, experienced less encapsulated blebs than those in the AGV group (P<0.05).
Conclusion:
The surgical outcomes of phaco-AGV showed higher success rates and fewer complications than those of AGV in this 2-year study.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview

